✦ LIBER ✦

Non-Small Cell Lung Cancer in Stages I–IIIB

✍ Scribed by Karl Wurstbauer; Hannes Weise; Heinz Deutschmann; Peter Kopp; Florian Merz; Michael Studnicka; Olaf Nairz; Felix Sedlmayer

Publisher: Springer
Year: 2010
Tongue: German
Weight: 285 KB
Volume: 186
Category: Article
ISSN: 0179-7158
DOI: 10.1007/s00066-010-2108-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival of Patients in Clinical Stages

Survival of Patients in Clinical Stages I–IIIb of Non-Small-Cell Lung Cancer Treated with Radiation Therapy Alone

✍ Anja Bollmann; Thomas Blankenburg; Johannes Haerting; Oliver Kuss; Wolfgang Schü 📂 Article 📅 2004 🏛 Springer 🌐 German ⚖ 300 KB

Phase I/II study of cisplatin, ifosfamid

Phase I/II study of cisplatin, ifosfamide and irinotecan with rhG-CSF support in patients with stage IIIB and IV non-small-cell lung cancer

✍ Akihisa Fujita; Hirotsugu Takabatake; Shigeru Tagaki; Kyuhichiro Sekine 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 80 KB

A phase I study of larotaxel (XRP9881) a

A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer

✍ Francisco Robert; Karen Harper; Judie Ackerman; Sunil Gupta 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 284 KB

Radiotherapy for stage I–II non-small ce

Radiotherapy for stage I–II non-small cell lung cancer

✍ Y. Okamoto; M. Murakami; T. Mizowaki; T. Nakajima; Y. Kuroda 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 81 KB

The role of radiation therapy for stage

The role of radiation therapy for stage IIIB non-small cell lung cancer: Impact of clinical nodal stage on survival

✍ Kazushige Hayakawa; Norio Mitsuhashi; Masaya Furuta; Yoshihiro Saito; Yuko Nakay 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 441 KB

Chemoradiation enhances response in stag

Chemoradiation enhances response in stage IIIB lung cancer

✍ Ron R. Allison; Alan Schulsinger; Kyu H. Shin; Vitune Vongtama 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 425 KB 👁 2 views

Upon workup, the vast majority of non-small cell lung cancer patients are unresectable. Classically these patients undergo external beam radiation alone to 6,000 cGy which results in a disappointing 8.9 month median survival and high local failure rate. To enhance response, radiation dose was escala